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Abstract (238 words) 19 
Objectives 20 
Limited awareness of cancer symptoms results in patient delay in seeking help, and 21 
contributes to delay in diagnosis. Few UK studies have investigated the potential for 22 
community pharmacists to facilitate earlier detection of cancer. This study aimed to 23 
investigate what actions patients take to manage their early cancer symptoms, to identify 24 
the extent of current community pharmacy involvement and to consider the potential role 25 
for community pharmacists to facilitate earlier diagnosis.  26 
Methods 27 
Patients diagnosed with lung, colorectal or gastro-oesophageal cancer in the preceding 28 
12 months were identified during clinic visits by consultants. Semi-structured interviews 29 
were conducted, audio-recorded, transcribed and thematically analysed, using the 30 
Framework Approach. 31 
Key findings 32 
Twenty-five consenting patients were interviewed: two-thirds were male and more than 33 
half had lung cancer. Although all had experienced potential cancer symptoms prior to 34 
diagnosis, most underestimated seriousness and mis-attributed causation. Symptoms 35 
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were managed by lifestyle changes and self-selecting medicines from local shops, 36 
supermarkets and pharmacies but without engaging with the pharmacist.  37 
Conclusion 38 
For symptom management, participants self-selected medicines from community 39 
pharmacies, but pharmacy staff were rarely involved. Involving community pharmacists 40 
or their staff at the point of sale of these medicines might have facilitated earlier cancer 41 
diagnosis. Further research is needed to quantify how many patients with symptoms 42 
suggestive of cancer present in community pharmacies, and to understand if a 43 
pharmacist’s role in facilitating symptom management and appraisal of potential cancer 44 
symptoms would be acceptable and effective, before developing any interventions.  45 
Keywords: cancer awareness, early detection, early diagnosis, pharmacy, early cancer 46 
symptoms 47 
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Introduction 53 
Earlier diagnosis of cancer improves performance status (1) and survival rates (2). 54 
Patients in the United Kingdom (UK) are diagnosed with more advanced disease than 55 
those in other European countries which may partly explain poorer UK survival (3). 56 
Delays in diagnosis occur at almost every stage of the cancer journey, but the biggest 57 
delay is between patients first noticing symptoms and consulting a GP (4). Evidence 58 
shows that patients often experience symptoms for months before a lung cancer 59 
diagnosis but don’t seek medical attention (5). This delay is considered long enough to 60 
have an effect on treatment outcomes (6). 61 
The National Awareness and Early Diagnosis Initiative (NAEDI) aims to reduce 62 
cancer mortality and improve cancer survival rates in the UK by promoting early 63 
detection (7). People are encouraged to seek early professional advice for “suspicious” 64 
symptoms that could be attributed to cancer (7). However, public awareness of these, 65 
and risk factors associated with cancer, is low (8-12). Some studies have proposed that 66 
more patient support in primary care, education about symptoms and research into 67 
patients’ self-management of symptoms could facilitate earlier presentation, prompt 68 
referral, and earlier diagnosis, potentially improving cancer outcomes (5,6).  69 
Most cancers produce early symptoms which are often mild, mimic minor illness and 70 
are self-treated using non-prescribed remedies (13). Lung and colorectal cancers, two 71 
of the three most common cancers in Scotland,; account for 27% and 18% of all cancer 72 
deaths respectively (14).These cancers have early symptoms (cough and changes in 73 
bowel habits/ rectal pain respectively) which could be associated with less serious 74 
conditions, and for which patients often seek advice and treatment from community 75 
pharmacy. 76 
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Approximately 90% of the UK population visits a community pharmacy annually (15), 77 
and patients value the self-care counselling they receive from pharmacists (16,17).  78 
However, there is limited UK research examining the contribution of community 79 
pharmacists to the early detection of cancer. 80 
In November 2010, The Royal Pharmaceutical Society of Great Britain (RPSGB) and 81 
the Roy Castle Lung Cancer Foundation (RCLCF) conducted an audit of the number 82 
of people with symptoms suggestive of lung cancer identified by community pharmacy 83 
staff (18). The following year the audit was repeated targeting colorectal cancer (19). 84 
These audits demonstrated that people, with signs and symptoms suggestive of lung or 85 
colorectal cancer, were presenting to community pharmacies and that pharmacists 86 
were able to advise these patients to seek medical attention, based on the type and 87 
number of presenting symptoms. However, referred patients were not followed up to 88 
establish if they attended a medical appointment and/or were subsequently diagnosed 89 
with cancer. Earlier research in America, investigating pharmacists’ ability to identify 90 
cancer signs and symptoms found that the majority of pharmacists were confident in 91 
their ability to identify symptoms of skin, breast and colorectal cancer but were less 92 
confident regarding other cancers. The participants rated further education on cancer 93 
symptoms as important. The researchers concluded that pharmacists could have an 94 
important role in early detection and prevention of cancer, but further education and 95 
evaluation of the impact of this on patient referrals and subsequent cancer diagnosis 96 
was necessary (20).  97 
In summary, current evidence suggests there is a need to raise general public awareness 98 
of cancer symptoms, to expedite earlier GP consultations amongst those with such 99 
symptoms. This paper reports on the qualitative phase of a larger programme of work and 100 
focuses on three types of cancer: lung, gastro-oesophageal and colorectal, since their early 101 
symptoms are often self-managed through community pharmacy. The aim was to 102 
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investigate what actions patients take to manage their early cancer symptoms, to identify 103 
the extent of current community pharmacy involvement and to consider the potential role 104 
for community pharmacists to facilitate appropriate management and appraisal of 105 
potential early cancer symptoms. 106 
Materials and Methods 107 
Study design, setting and participants 108 
 A single qualitative, interview-based study was conducted with patients recruited 109 
from cancer outpatient clinics at Aberdeen Royal Infirmary, between January and 110 
August 2012. Participants were over 17 years of age, had received a diagnosis of 111 
gastro-oesophageal (GO), lung or colorectal cancer in the previous 12 months, and 112 
were considered, by their clinician, able to participate in the study and provide 113 
informed consent. The target recruitment was estimated at 30 patients: 15 from each 114 
of the lung, and gastro-intestinal oncology clinics however, when no new emerging 115 
themes were identified after two consecutive interviews (data saturation)no further 116 
interviews were conducted.  117 
Participant identification and recruitment 118 
Consecutive eligible patients were identified by the responsible clinician during 119 
outpatient clinics over an eight-month period and were given a study information pack. 120 
With their permission, they were referred to FN (a female pharmacist researcher, 121 
undertaking a PhD and with five years research experience) who was present in the 122 
clinic and was previously unknown to them. FN described the study, and recorded the 123 
contact details of patients interested in participating. FN contacted patients one week 124 
later to obtain their verbal consent to participate and arrange a time for their one-to-125 
one interview. Those declining consent were not contacted again. 126 
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Written consent was obtained immediately prior to conducting the face-to-face, audio-127 
recorded, interviews (30-60 mins long), which were conducted at a mutually 128 
convenient site (home or university) by FN.. A pre-piloted, semi-structured, topic 129 
guide (see supplementary material), informed by the literature (4,6,8,10,12,21-25), 130 
was used to establish the participant’s awareness, experience and assessment of their 131 
cancer symptoms, and obtain basic demographic information . The topic guide 132 
explored participants’ actions to manage their symptoms, including any community 133 
pharmacy involvement. 134 
A Landmark Calendar Instrument (26-28), was used to aid participants’ recall of 135 
symptoms and time frames. Symptom lists for the three cancers were developed from 136 
published sources (29-36) and were used at interview as prompts to identify symptoms 137 
participants may have experienced but had not attributed to their cancer. 138 
Data analysis and reporting 139 
Interview recordings were transcribed verbatim by FN, and a 10% (n=3) random 140 
sample was independently checked for transcription accuracy by TP. Transcripts were 141 
anonymised; participants were identified only by a unique ID number, their sex, age 142 
and cancer type. 143 
Data was stored and managed using Nvivo 9 (37). Content analysis was conducted 144 
using The Framework Approach (38). A coding framework was developed by FN and 145 
independently validated by all members of the research team. The framework was 146 
iteratively revised as new themes emerged. All transcripts were coded by one person 147 
(FN), and a 10% (n=3) random sample of coded transcripts was independently double 148 
coded by TP to check coding accuracy and consistency.  149 
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A thematic framework (Error! Reference source not found.) was developed based 150 
on emergent key themes which were then synthesised into broader concepts. 151 
Recruitment, interviewing, transcription and analysis were carried out simultaneously. 152 
Direct quotes from transcripts are presented in Table 2 and assigned to the appropriate 153 
participant using the following identification format: [Male/Female, Age band, Cancer 154 
Type]. 155 
Approval to undertake the project was granted by the North of Scotland Research 156 
Ethics Committee (1) 11/ NS/0028 on 27th October 2011.  157 
Results 158 
Participant characteristics 159 
Of the 35 patients contacted by the researcher, eight were too unwell or declined to 160 
participate, 25 were interviewed before data saturation was achieved and recruitment 161 
was stopped and the remaining two were thanked for their interest but were not 162 
interviewed. Participant characteristics are summarised in Table 3. There was no 163 
suggestion of any influence of age or gender across the different cancer types. The 164 
Landmark Calendar revealed the period of longest delay was the time between the 165 
participants’ first experiencing symptoms and consulting their doctor (patient 166 
delay)(21) and varied from zero to 10 months. 167 
Findings are reported under four main concepts: symptoms experience and appraisal; 168 
strategies for self-management of symptoms; triggers and barriers to help-seeking 169 
behaviour and sources of help.  170 
 171 
Symptoms experience and appraisal 172 
Prior to prompting with a symptoms list, participants identified specific ‘first’ 173 
symptoms: breathlessness, lethargy and cough (lung cancer participants); rectal pain 174 
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(colorectal cancer participants); and pain or difficulty swallowing (GO cancer 175 
participants). However, participants also commonly experienced non-specific 176 
symptoms they struggled to define (Quote 1). Lack of energy and tiredness were 177 
consistently mentioned, as having most impact on them and their daily activities 178 
(Quote 2). A minority of patients were unaware of experiencing any symptoms and 179 
cancer was diagnosed incidentally as a result of an unrelated hospital admission or 180 
atypical or sudden onset of acute symptoms, for example. one participant reported 181 
coughing up blood, another reported leg pain as their first symptom (Quote 3). Another 182 
recalled no symptoms at all, but admission to hospital, after falling in the street, 183 
resulted in opportunistic detection of lung cancer. 184 
Symptoms impacted on family lives and ability to engage in family celebrations. While 185 
family members expressed concern about the participants’ symptoms, particularly 186 
weight loss, participants frequently reported not being emotionally affected by their 187 
symptoms until they worsened and persisted (Quote 4). 188 
There was a widespread lack of awareness of risk factors and ‘red-flag symptoms’ 189 
associated with cancer. Unless participants experienced progressively worsening pain 190 
or unexplained bleeding, they did not assess their initial symptoms as serious, 191 
dismissing them or associating them with their lifestyle (smoking or eating habits), 192 
minor illnesses (piles, cold or indigestion), injuries (pulled muscle, cracked ribs), their 193 
age or other pre-existing medical condition (MS, heart conditions) (Quote 5). Some 194 
participants did not attribute their symptoms to anything until they were diagnosed and 195 
the majority never thought they had cancer (Quote 6). 196 
All participants reported experiencing at least one symptom, when prompted with the 197 
relevant symptom list, which they had not attributed to their cancer prior to the 198 
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interview. Symptoms most frequently reported were weight loss and tiredness, with 199 
breathlessness, cough, loss of appetite and hoarseness also commonly reported. 200 
 201 
Strategies for self-management of symptoms  202 
Participants took different actions to manage their initial symptoms: few consulted 203 
their doctor, but more than half self-managed their symptoms using over-the-counter 204 
medicines purchased from a pharmacy or supermarket, or which they had at home e.g. 205 
cough mixtures, lozenges, haemorrhoid treatments, indigestion/reflux remedies and 206 
analgesics. Participants who attended a community pharmacy tended to self-select 207 
medicines rather than ask for advice: only three participants sought symptom advice 208 
from pharmacy staff. Participants did not consistently purchase medicines from the 209 
same place, but when they did, frequent purchases of the same medicine were 210 
unchallenged (Quote 7).  211 
Some participants implemented lifestyle changes to manage their symptoms, for 212 
example,. changes to their diet, drinking water to facilitate swallowing, resting or 213 
sleeping and a few tried alternative therapies (Quote 8). 214 
However some participants took no medicines or action to manage their symptoms. 215 
They thought their symptoms would go away or tried to forget about them and 216 
continued on with their daily routine. 217 
 218 
Triggers and barriers to help-seeking behaviour 219 
The main triggers for seeking professional help were worsening or unresolved 220 
symptoms, new additional symptoms, or an increasing awareness of their symptoms 221 
impacting on their normal activities. Participants frequently reported being encouraged 222 
to attend their GP by friends/family, but did not always act on this. Occasionally, 223 
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previous experience of illness with similar symptoms triggered help-seeking 224 
behaviour, however, their attribution of symptoms to their previous illness was 225 
incorrect (Quote 9). The main barriers to accessing help were participant related and 226 
linked to symptom awareness and appraisal.  227 
 228 
Sources of help 229 
Most discussed their symptoms with their immediate family and/ or close friends.  230 
Some participants stated they would go to their GP if they were ill and needed help 231 
from a health care professional, but they frequently reported only visiting the doctor 232 
when absolutely necessary, and expressed concern about wasting health professionals’ 233 
time. Others cited lack of faith in their GP practice, attitude of the GP and reception 234 
staff, a dislike of hospitals, a dislike of taking medicines, a fear of catching other ‘bugs’ 235 
while in hospital, embarrassment about the symptoms or the area of the body affected, 236 
and living in a remote area as barriers to accessing help from their GP (Quote 10). 237 
A few participants chose to visit a pharmacy before seeking help from their GP. 238 
Although the majority of these did not speak to counter staff or the pharmacist, the 239 
three who asked for a pharmacist’s advice were appropriately referred and were happy 240 
with the advice and treatment given (Quote 11). Participants were unaware of the 241 
advisory role of pharmacists, with most considering the pharmacy role as one of 242 
medicines supply. They therefore, had not considered visiting a pharmacy for help 243 
(Quote 12). However, some expressed the view that pharmacists had a bigger role in 244 
healthcare delivery (Quote 13).  245 
The main barrier to accessing pharmacy support was a lack of awareness that 246 
pharmacists were suitably skilled to respond appropriately to their symptoms (Quote 247 
14). Others included perceived lack of privacy, the openness of the premises, the 248 
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pharmacy being busy, the age and sex of the counter staff and a reluctance to be 249 
questioned about their symptoms. 250 
Discussion 251 
This exploratory interview study found that people with early symptoms of cancer purchase 252 
OTC medicines, sometimes from a pharmacy, rarely seeking advice from a pharmacist and 253 
with frequent purchases of the same medicine remaining unchallenged.   Although, few 254 
interviewees sought a pharmacist’s advice about their symptoms, those that did were 255 
appropriately referred, however there was a general lack of awareness regarding the 256 
pharmacist’s skills and knowledge or role beyond that of medicines supply; In addition 257 
barriers to accessing pharmacy services were identified.  258 
 259 
This study also found that participants demonstrated a lack of knowledge regarding cancer 260 
related and ‘red-flag’ symptoms. This resulted in a failure to both recognise and appraise 261 
early cancer symptoms and lead to participants employing a variety of inappropriate 262 
strategies and delays in seeking advice from healthcare professionals, and diagnosis.  Other 263 
strategies for symptom management included discussing their symptoms with their 264 
friends/family; and lifestyle changes. New or worsening symptoms, lay advice, or 265 
symptoms that interfered with their daily activities, prompted patients to access services 266 
and their first choice, when seeking help, was their GP.   267 
 268 
This qualitative study highlights critical points in the patient journey when community 269 
pharmacy could have intervened and provides further insights into some of the reasons for 270 
patient delay. 271 
 272 
  
Strengths and Limitations of study 273 
Strengths 274 
This is the first published study to investigate how people with cancer have, or could 275 
have, interacted with a community pharmacy in the lead-up to their cancer diagnosis in 276 
order to inform a potential role for community pharmacy in earlier diagnosis.  277 
The research methods used were robust: participants were recruited by the consultants 278 
from clinics rather than community pharmacies to reduce the risk of bias towards regular 279 
community pharmacy users; the interview schedule was informed by current literature; 280 
interview transcripts were all coded by the same person, eliminating the potential for inter 281 
coder variation; participants were unaware the researcher was a pharmacist reducing the 282 
risk of bias in interview responses; a recognised robust approach (the Framework 283 
Approach) was used to analyse, interpret and synthesise the data; the transcription, coding 284 
and data entry were all independently validated and a landmark calendar facilitated 285 
participant recall.  286 
 287 
Limitations 288 
The sample was two thirds male and one third female. The cancers under investigation are more 289 
prevalent in males than females, which may explain the apparent over-representation of males in 290 
the sample. Since males are less likely to visit community pharmacies (39) this may have impacted 291 
on the extent to which our participants had accessed pharmacy services. The population in this 292 
study was older so their symptom management behaviour may not reflect that of the overall a 293 
population. It is not known how many patients were approached to participate or how many 294 
declined to speak to the researcher, because Ethics denied the request for the consultants to 295 
complete a tally of clinic patients with this detail. 296 
  
 297 
Implication for community pharmacy 298 
Previously pharmacies were the most common source for OTC medicines (40), however, 299 
participants in our study frequently made purchases from supermarkets, and/or repeat 300 
purchases from more than one pharmacy, limiting opportunities for pharmacists to interact 301 
with patients or for patterns of purchasing to be noted.  302 
Medicines deregulation was introduced to increase safe and convenient public access to 303 
medicines, and reduce GP workload for managing minor ailments. However, further 304 
deregulation means medicines are more widely available.  Accessing medicines from non-305 
regulated outlets diminishes the status of medicines to that of commodity items, reinforcing 306 
the perception that symptoms treated by these medicines are therefore minor. In this study 307 
self-medicating with self-selected OTC medicines at both pharmacies and supermarkets 308 
was the most popular strategy for management of early symptoms and represents a missed 309 
opportunity for interaction with a healthcare professional. The continued purchase and use 310 
of OTC medicines from a variety of sources, removed the opportunity for pharmacists to 311 
intervene, provide appropriate advice, facilitate accurate symptom appraisal and reduce 312 
inappropriate medicines use, which could potentially have led to earlier referral and 313 
diagnosis. 314 
Although some participants visited community pharmacies, they rarely sought 315 
pharmacist’s advice about their symptoms and multiple purchases of the same medicine 316 
over a short period of time were unchallenged. This study showed participants lacked 317 
awareness of the pharmacist’s role, beyond supplying medicines that is, the provision of 318 
professional advice and information regarding symptoms without the requirement. 319 
Pharmacists and their staff should be more pro-active in engaging patients in discussion 320 
  
about their symptoms since in this study, those who asked the pharmacist for help were 321 
happy with the support they received and acted on their advice. Community pharmacists 322 
have been shown to appropriately advise patients presenting at a community pharmacy 323 
with potential cancer symptoms, to seek medical attention (18,19). Raising public 324 
awareness of the knowledge and advice available from pharmacists, their ability to 325 
recognise and appraise symptoms, and make appropriate referrals, could encourage 326 
increased pharmacy consultations.  327 
To increase patient consultations with community pharmacists about potential cancer 328 
symptoms, identified barriers such as lack of privacy, the pharmacy being busy, the age 329 
and sex of the counter staff and a reluctance to be questioned about their symptoms, should 330 
be minimised. This could be done by encouraging use of consultation rooms, upskilling 331 
dispensing staff to allow pharmacists time to address the patients’ needs, improving the 332 
communication, questioning and empathic skills of the pharmacy staff and ensuring they 333 
are appropriately trained in symptom management and when to refer to the pharmacist. The 334 
findings of this study, therefore, have implications for the development of any potential 335 
intervention to improve detection of early cancer symptoms. 336 
 337 
Other findings in the context of the literature 338 
Our findings, show lack of awareness of symptoms, risk factors, and ‘red-flag symptoms’ 339 
and failure to assess symptoms as those of an illness, contribute to delay. These findings 340 
are reflected in the substantial body of evidence established in the published literature (1,8-341 
12,41). The evidence strongly suggests that these are key factors in cancer patients’ delayed 342 
presentation and that identification of the existence of an illness is a necessary condition 343 
  
for seeking help. More accurate symptom appraisal may, therefore, expedite GP 344 
consultation. 345 
Consistent with published literature (42), our study identified the period of ‘patient delay’ as a 346 
potential point in the patient journey to implement effective interventions to promote 347 
appropriate help-seeking behaviour. Similarly the help-seeking triggers identified in this study 348 
have previously been documented (41,43,44) 349 
Areas for Further Research 350 
This study has identified some interaction with community pharmacy but has also 351 
identified a number of missed opportunities where current community pharmacy services 352 
could be developed to enable pharmacists and their staff to take a role in the earlier 353 
detection of cancer. Developmental research is now required to devise interventions which 354 
address the missed opportunities for community pharmacists to facilitate earlier diagnosis 355 
of cancer. This research should follow the MRC Framework for developing complex 356 
interventions prior to proposing any community pharmacy based intervention.  357 
 358 
Conclusion 359 
Despite recent awareness campaigns people still fail to recognise their cancer symptoms, 360 
they self-medicate and delay seeking help. In this study many of the participants attended 361 
community pharmacies to purchase medicines but did not interact with pharmacist about 362 
their symptoms. Those who did interact with the pharmacist were referred and were 363 
subsequently diagnosed with cancer confirming appropriateness. Thus, there is potential 364 
for more community pharmacist involvement in both advising on symptoms and referring 365 
on. However for this to happen patients need to make more use of pharmacists’ skills. 366 
Further research is needed prior to developing any intervention. 367 
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Table 1 Thematic Framework 
 
1. Participant profile 
 
 1.1 Age band 
1.2 Gender 
1.3 Type of cancer 
1.4 Smoking status 
1.5 Drinking status 
1.6 Residence 
1.7 Perceived personal health status 
1.8 Co-morbidities   
1.9 Awareness of red flag symptoms or risk factors 
1.10 Previous experience of illness 
2. Symptom experience and assessment 
 
 2.1 Experience and description of symptoms  
2.2 Impact of symptoms 
2.3 Assessment and attribution of symptoms 
2.4 Other symptoms identified from lists 
3. Strategies for Self- Management of symptoms 
 
  
 
 
3.1 Took no action or ignored symptoms 
3.2 Self-medication with OTC medicines 
3.3 Lifestyle changes 
3.4 Discussions with friends and family 
3.5 Information gathering 
3.6 Alternative therapy 
4. Triggers and barriers for other Help-Seeking behaviour 
 
 4.1 Triggers for other help-seeking behaviour 
4.2 Barriers to help-seeking behaviour 
5. Contact with healthcare professional  
 
 5.1 GP 
5.2 Hospital     
5.3 Pharmacy  
5.4 Contact with NHS24 or alternative therapists 
6. Timelines  
 
  6.1 From awareness of initial symptom to first GP appointment 
6.2 First GP appointment to first hospital appointment 
6.3 First hospital appointment to diagnosis 
6.4 Awareness of initial symptom to diagnosis 
7. Understanding and feelings about diagnosis and prognosis 
 
  7.1 Understanding of diagnosis 
7.2 Understanding of prognosis 
7.3 Feelings about diagnosis and prognosis 
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Table 2 Participant Quotes 
Quote 
No 
Quote Participant 
1 ‘Basically my symptoms were one of just not feeling 
100%.’  
 
Male,60-69,GO cancer 
 
2 ‘My windows weren’t cleaned, my garden wasn’t done,  
the hoovering wasn’t done and the dusting wasn’t done.  
Just everyday things that should’ve been done weren’t 
being done. … Personal care started to fail, I mean, I’ve 
always been an active person. I never 
 sit about. And for me to be lying on the sofa … Changed 
me completely.’  
 
Female, 60-69, Lung cancer 
 
3 ‘I don’t think there were any, …  real symptoms. The only 
symptom was my legs were sore. That’s all there was.’ 
 
Male, 50-59, Lung cancer 
 
4 ‘But then I knew after a few weeks of not getting better 
then that’s unnatural.  ... so it’s very unnatural for me to 
be ill so much … by the time I got to the third doctor I 
was getting really, sort of, disappointed that things 
weren’t being addressed in a … in a perhaps a more 
aggressive manner,’  
 
Male, 60-69, GO cancer 
5 ‘Well the results of having been smoking … I thought the 
smoking had reduced my lung function. Not necessarily 
because there was a tumour there, but because people 
that smoke a lot become short of breath.’  
 
Male, 60-69, Lung cancer 
6 
 
‘I had no idea why the tiredness was happening…  I mean 
I was still eating, I was still having’ a good diet …  I’d 
no idea what it was. I’d no idea, until I’d got the CT scan 
and it was diagnosed lung cancer … It wasn’t ‘til later 
on when it was diagnosed and I was told some of the 
symptoms, that I realised -Well yes I’ve had that all 
summer holidays,’ 
 
Female, 70-79, Lung cancer 
7 ‘But I was going through too many bottles of it …  When 
the cough was at its worst I would probably polish off 
one bottle a day. I’d have the first ‘swig’ in the morning 
and then a ‘swig’ at dinner time, and a really big ‘swig’ 
… basically what was left at night. Then I’d go and get 
another bottle.’  
 
Male, 60-69, Lung cancer 
8 ‘I was choosing what I would eat because I couldn’t take 
in any meats, I was going for very soft foods …  if I could 
Male;40-49;G cancer 
 
 
  
avoid a meal I would at the time because the eating was 
so painful.’ 
  
9 ‘No … until they told me about the brain tumour 
[secondary to lung cancer], I thought it was going to be 
a recurrence of the MS.’  
 
Male;60-69; Lung cancer 
10 ‘because we’ve moved around about, we’ve had several 
different Dr’s practices, and the one we’ve currently got 
is probably the one we’ve got least confidence in….. it’s 
just probably the reaction to the individual, just doesn’t 
give you a great deal of confidence.’ 
 
Male, 60-69, GO cancer 
11 ‘ couldn’t have been more helpful, neither could’ve the 
girl that was serving me, … she went and got the 
pharmacist and she came back. So I mean definitely very, 
very helpful ... I did tell her that I had the cough and 
things so. And she did say if it didn’t help go back to your 
doctor.’  
 
Female, 70-79, Lung cancer 
12 ‘I just think that … with something like that if you’re 
going to get it seen to it’s best getting it seen to by the 
proper people ….well the specialists in the field … 
people that know exactly what they’re speaking about.  
Although some pharmacists are very good, I don’t think 
they’ve a … vast knowledge of things outside their own 
field.’  
 
Male, 70-79, Lung cancer 
13 ‘The pharmacists are experienced people and can help 
and I don’t think we use them to the full benefit.’  
 
Female, 70-79, Lung cancer 
14 ‘I’m either well or I go to the doctor…That’s it…….you 
would need to make people aware that they 
(pharmacists) have the ability and I don’t think that we 
would consider that they have the ability …  So we just 
go to the doctors.’ 
 
Male, 60-69, GO cancer 
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Table3 Participant Characteristics n(%) 
 n=25 
 
% 
Sex 
Male 17 68 
Female 8 32 
Age 
30-39 1 4 
40-49 1 4 
50-59 1 4 
60-69 12 48 
70-79 9 36 
80 or 0ver 1 4 
Type of cancer 
Lung 14 56 
GO 7 28 
Colorectal 4 16 
Smoking status 
Smoker 6 24 
Ex-smoker 15 60 
Non-smoker 4 16 
Alcohol status 
Drinks daily 6 24 
Drinks occasionally 8 32 
Stopped because of 
illness 
4 16 
Never drinks 7 28 
Residence 
Urban 12 48 
Rural 9 36 
Suburban 4 16 
 
 
  
A few questions for background information 
 
1. Patient demography (structured) 
Gender   male     female 
 
Age   18-29  30-39  40-49  50-59  60-69      70-79        80 or over 
 
Smoker  YES  NO   
 
If yes,  How much               
 
When started    
 
Drinker YES  NO 
 
If yes  How much     
 
How often  
 
TOPIC GUIDE INTERVIEW - Understanding patients’ self-management of early cancer symptoms and exploring the  
  potential role of community pharmacy in earlier diagnosis. 
Participant identification number                    □□□ 
  
 
 
 INTERVIEW QUESTIONS PROBING QUESTIONS 
 
1. What have the doctors told you about your illness? 
 
Primary / secondary 
Using the Personal Landmark Calendar Instrument would 
you identify some personally important dates using the pen 
supplied  
 
for example birthdays, anniversaries, 
 holidays etc 
THINKING ABOUT TIME SCALES 
Would you indicate on the calendar: 
 
When you first noticed any changes in your body 
When you first thought you should discuss these changes 
with a healthcare professional  
When you first discussed these changes with your doctor 
And finally when you were given your diagnosis 
 
 
 
 
Any signs or symptoms 
 
 
e.g. nurse, doctor,  pharmacist 
Investigations- Instigated by ?? 
2. Before you were aware of these changes (signs or 
symptoms) -How would you describe your health?  
 
3. Before you experienced these symptoms were you aware 
of any warning symptoms you should look out for? 
Previous experience of cancer- friends family etc 
 
 
4. What were the first changes to your body you remember? 
(see checklist of symptoms for each of the two cancers 
attached) 
Unprompted first  
Then prompt with symptom list 
5. How did these symptoms affect you? Physically- 
emotionally 
interfere with your normal daily activities? 
concerned, worried, scared, stressed, anxious, frustrated? Why? 
6. At that point, what did you think might be causing your 
symptoms? 
 
Why? 
 
7. Tell me what you did about your symptoms? 
 
 
e.g. medicines, alternative therapies nothing? 
Who/ Why? When? Where? How? 
8. Did you speak to any friends or family about your 
symptoms or how you were feeling? 
 
 
Why? When? 
How long had you had the symptoms before speaking to them?  
Who did you talk to? 
What did they say/do? 
  
 INTERVIEW QUESTIONS PROBING QUESTIONS 
 
9. Did their response influence what you then thought or did 
about your symptoms? 
 
In what way? 
10. Did you have any contact with healthcare professionals, 
other than doctors, to help manage your early symptoms?  
 
Who? When? Why? 
e.g. community pharmacy, nurse, dietician, physiotherapist 
(pharmacy staff, nhs 24 etc) 
11. If not -why not? –too busy, other priorities- Didn’t think you needed to- Too far away, 
convenience 
12. Did you have any contact with any alternative therapy 
providers to help manage your symptoms? 
 
e.g. acupuncturist, herbalist, reiki therapist etc 
Who? When? Why? 
13. Why did you choose to speak to that healthcare 
professional or therapist about how you were feeling/ 
symptoms? 
previous experience, convenience, peers, family, friends, cost 
If the participant did visit a community Pharmacy 
14. Did you ask for advice in the pharmacy? Why? 
When? 
15. Tell me about your visit(s) to the pharmacy Information given to staff/pharmacist 
How did they respond?  -What did they ask you? 
medicines /advice/information/ follow up  
who you spoke to-the pharmacy staff and /or the pharmacist? 
16. After the visit(s) to the pharmacy what did you do about 
your symptoms 
 
Pharmacy visit influenced action? 
17. What affect did the interaction with the staff/pharmacist 
have on you and the management of your symptoms? 
 
Physically, emotionally, Symptom relief?-less worried, more worried 
18. Were you happy with the interaction with the 
pharmacist/staff? 
Why? 
What was good about it? What was not so good? 
 
 
 
 
  
 
 
 
 INTERVIEW QUESTIONS PROBING QUESTIONS 
 
If the participant did NOT visit a community Pharmacy 
 
19. Did you ever consider visiting a community pharmacy 
about your early symptoms? 
 
If yes-What made you change your mind? 
 
20. Why didn’t you use community pharmacy services? 
 
Symptoms not severe, didn’t want to bother them, not a priority-other things 
going on 
Too far away 
21. At the point when you thought you should discuss 
these changes with your doctor what did you think was 
causing your early symptoms/ changes to your body? 
How did this make you feel? 
 
22. What prompted you to seek medical advice from a doctor Did you decide yourself – Why 
or did someone else suggest it?  A friend, a family member, healthcare 
professional, therapist  
Change in symptoms from first experience 
23. Tell me what you did at this point Why? 
self-belief in managing symptoms, fear, priorities,  
24. What did you think might be wrong with you? Did you think you might have cancer? 
Why? 
 
 
 
 
 
 
 
 
 
 
